For the Treatment and Prevention of Venous Thromboembolism, Bayer/Ortho-McNeil’s Xarelto Will Earn Peak-Year Sales of $500

However, Xarelto’s Overall Uptake Could Be Constrained By a Perception of an Increased Risk of Bleeding in Patients, According to Findings from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that, following its expected launch in the United States in 2012 for venous thromboembolism (VTE) prophylaxis in medically ill patients, the overall uptake of Bayer/Ortho-McNeil’s Xarelto (rivaroxaban) could be constrained in this indication by a perception of an increased risk of bleeding. Nonetheless Xarelto will achieve blockbuster potential in the world’s major pharmaceutical markets.

The Pharmacor 2011 findings from the topic entitled Venous Thromboembolism reveal that, following the recently released MAGELLAN clinical trial data that demonstrated Xarelto’s non-inferiority over Sanofi-Aventis’s Lovenox (the current standard of care for VTE) in the first phase of the trial, Decision Resources forecasts Xarelto will earn peak-year VTE sales of $500 million to $1 billion in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

“We expect that the MAGELLAN trial subgroup analyses will reveal patient groups where Xarelto has a favorable risk-benefit profile,” said Decision Resources Analyst Matthew Killeen, Ph.D. “Although these subgroup analyses will enable this oral factor Xa inhibitor to secure approval in the United States for the potentially lucrative indication of VTE primary prophylaxis in medically ill patients, a perception of an increased risk of bleeding could constrain its uptake.”

The Pharmacor 2011 findings also reveal that Decision Resources expects Bristol-Myers Squibb/Pfizer’s Eliquis (apixaban) to perform well in the ADOPT clinical trial, owing to its bleeding profile seen in other clinical studies and its lower level of renal clearance as compared to other novel oral anticoagulants.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources, Inc.
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.